Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to personalize cervical cancer treatment after radiation

NCT ID NCT07153952

Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 60 people with cervical adenocarcinoma to see how their tumors respond to radiotherapy. Researchers will use imaging and tissue samples to better predict outcomes and guide next steps, like surgery or additional treatment. The goal is to improve monitoring and tailor care for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiotherapy
What this could lead to
If successful, this could lead to better ways to monitor treatment response and personalize care for cervical adenocarcinoma patients after radiotherapy.
What could go wrong
This is an early-phase observational study with only 60 participants, so results may not apply broadly. It focuses on understanding, not testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathological diagnosis of cervical adenocarcinoma; 2. Age 18-80 years old; 3. FIGO 2018 stage IB3-IVA; 4. Karnofsky score≥60 points; 5. Complete blood count, and comprehensive metabolic panel meet the conditions for CCRT; 6. No metal implants in the body, and can perform MRI examination; 7. Willing to participate in this study and provide written informed consent. Exclusion Criteria: 1. Patients who have received pelvic radiotherapy before; 2. Patients whose target tumors have been treated before (chemotherapy, immunotherapy, surgical treatment, etc.); 3. Allergy to iodine contrast agent; 4. Participating in other clinical studies that may affect the results of this study (determined by the principal investigator); f) Serious diseases that may significantly affect compliance with clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment; g) Other situations that the investigator believes are not suitable for participation in this clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical adenocarcinoma cervical adenosquamous carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical adenocarcinoma Cervical adenosquamous carcinoma Radiotherapy

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.